Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha variable 27 (TRAV27) is a protein segment encoded within the TCR alpha gene locus and forms part of the variable region of the T cell receptor (TCR) alpha chain[1][3][5]. As a variable (V) gene segment, TRAV27 recombines with joining (J) segments during T cell development to contribute to the vast diversity of TCRs, enabling T cells to recognize a wide range of peptide antigens presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells[1][2][7]. TRAV27 itself is a germline-encoded DNA segment and is not a surface receptor or standalone protein, but a building block of the TCR alpha chain variable domain[1][3]. The TCR complex is essential for T cell activation and adaptive immune response signaling, but no drugs or therapies target individual V gene segments like TRAV27[1][8]. Instead, TRAV27 is studied in immunogenetics and T cell repertoire analysis to understand antigen-specific immune responses[1].
Not directly applicable (target is a V segment of the TCR; monoclonal antibodies or cell therapies may target the whole TCR, but not this segment specifically)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha variable 27 (TRAV27).